Literature DB >> 17645873

Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5.

K Leach1, S J Charlton, P G Strange.   

Abstract

The chemokine receptor, CCR5, responds to several chemokines leading to changes in activity in several signalling pathways. Here, we investigated the ability of different chemokines to provide differential activation of pathways. The effects of five CC chemokines acting at CCR5 were investigated for their ability to inhibit forskolin-stimulated 3'-5'-cyclic adenosine monophosphate (cAMP) accumulation and to stimulate Ca(2+) mobilisation in Chinese hamster ovary (CHO) cells expressing CCR5. Macrophage inflammatory protein 1alpha (D26A) (MIP-1alpha (D26A), CCL3 (D26A)), regulated on activation, normal T-cell expressed and secreted (RANTES, CCL5), MIP-1beta (CCL4) and monocyte chemoattractant protein 2 (MCP-2, CCL8) were able to inhibit forskolin-stimulated cAMP accumulation, whilst MCP-4 (CCL13) could not elicit a response. CCL3 (D26A), CCL4, CCL5, CCL8 and CCL13 were able to stimulate Ca(2+) mobilisation through CCR5, although CCL3 (D26A) and CCL5 exhibited biphasic concentration-response curves. The Ca(2+) responses induced by CCL4, CCL5, CCL8 and CCL13 were abolished by pertussis toxin, whereas the response to CCL3 (D26A) was only partially inhibited by pertussis toxin, indicating G(i/o)-independent signalling induced by this chemokine. Although the rank order of potency of chemokines was similar between the two assays, certain chemokines displayed different pharmacological profiles in cAMP inhibition and Ca(2+) mobilisation assays. For instance, whilst CCL13 could not inhibit forskolin-stimulated cAMP accumulation, this chemokine was able to induce Ca(2+) mobilisation via CCR5. It is concluded that different chemokines acting at CCR5 can induce different pharmacological responses, which may account for the broad spectrum of chemokines that can act at CCR5.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17645873     DOI: 10.1016/j.bcp.2007.06.019

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  Pharmacological modulation of chemokine receptor function.

Authors:  D J Scholten; M Canals; D Maussang; L Roumen; M J Smit; M Wijtmans; C de Graaf; H F Vischer; R Leurs
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions.

Authors:  L T May; S J Briddon; S J Hill
Journal:  Mol Pharmacol       Date:  2010-01-19       Impact factor: 4.436

3.  An arrestin-dependent multi-kinase signaling complex mediates MIP-1beta/CCL4 signaling and chemotaxis of primary human macrophages.

Authors:  Ricky Cheung; Mobeen Malik; Vipa Ravyn; Brian Tomkowicz; Andrzej Ptasznik; Ronald G Collman
Journal:  J Leukoc Biol       Date:  2009-07-20       Impact factor: 4.962

Review 4.  Co-receptor signaling in the pathogenesis of neuroHIV.

Authors:  E A Nickoloff-Bybel; L Festa; O Meucci; P J Gaskill
Journal:  Retrovirology       Date:  2021-08-24       Impact factor: 4.602

Review 5.  Toxins-useful biochemical tools for leukocyte research.

Authors:  Susana Cubillos; Johannes Norgauer; Katja Lehmann
Journal:  Toxins (Basel)       Date:  2010-03-26       Impact factor: 4.546

6.  Effects of CCR5 59029G/A polymorphism on the risk to diabetic nephropathy.

Authors:  Mingfeng Cao; Zhenhua Tian; Lin Zhang; Ruiting Liu; Qingbo Guan; Jinjiao Jiang
Journal:  Oncotarget       Date:  2017-10-30

7.  Development of a high-throughput fluorescent no-wash sodium influx assay.

Authors:  Bryan Tay; Teneale A Stewart; Felicity M Davis; Jennifer R Deuis; Irina Vetter
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.